<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02491281</url>
  </required_header>
  <id_info>
    <org_study_id>CLNA043X2101</org_study_id>
    <nct_id>NCT02491281</nct_id>
  </id_info>
  <brief_title>First-in-human Single Ascending Dose Study of LNA043 in Patients Scheduled for Total Knee Replacement</brief_title>
  <official_title>A Randomized, Placebo Controlled, Double-blind First-in-human Single Ascending Dose Study of LNA043 in Primary Osteoarthritis Patients Scheduled for Total Knee Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety and tolerability of ascending single doses of&#xD;
      LNA043 given intra-articularly into the human knee joint prior to its removal at total knee&#xD;
      replacement surgery. In addition, this will help to establish the presence of LNA043 within&#xD;
      the articular cartilage, assess pharmacokinetics and immunogenicity, and will allow&#xD;
      exploration of biomarkers of hyaline cartilage repair.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 16, 2015</start_date>
  <completion_date type="Actual">March 6, 2018</completion_date>
  <primary_completion_date type="Actual">February 7, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety endpoints (including number of adverse events CTC-AE, physical exam, vital signs, ECG, safety laboratory and pain measured using KOOS)</measure>
    <time_frame>Up to and including 7 days post-dose</time_frame>
    <description>Safety and tolerability of LNA043 after one intra-articular injection into the knee of osteoarthritis patients scheduled for total knee replacement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunohistochemical staining for LNA043 in knee cartilage</measure>
    <time_frame>1 up to 4 weeks post-dose</time_frame>
    <description>Joint presence and persistence of LNA043 within the cartilage of the knee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of LNA043 in serum and synovial fluid</measure>
    <time_frame>Pre-dose, Day 1, Day 4, Day 8, and Day 36</time_frame>
    <description>LNA043 pharmacokinetics in serum and concentration in synovial fluid to determine local and systemic exposure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of ANGPTL in serum and synovial fluid</measure>
    <time_frame>Pre-dose, Day 1, Day 4, Day 8, and Day 36</time_frame>
    <description>ANGPTL levels in serum and the synovial fluid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of anti-LNA043</measure>
    <time_frame>Pre-dose, Day 8, and Day 36</time_frame>
    <description>Immunogenicity in serum</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Primary Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery</condition>
  <arm_group>
    <arm_group_label>LNA043</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LNA043 given intra-articularly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given intra-articularly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LNA043</intervention_name>
    <description>ascending single dose on Day 1; 1 to 4 week(s) prior total knee replacement surgery</description>
    <arm_group_label>LNA043</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>ascending single dose on Day 1; 1 to 4 week(s) prior total knee replacement surgery</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients age 50 to 75 years of age inclusive, and in good health as&#xD;
             determined by past medical history, physical examination, vital signs,&#xD;
             electrocardiogram, and laboratory tests at screening&#xD;
&#xD;
          -  Patients diagnosed with primary osteoarthritis of the knee assessed locally for whom a&#xD;
             total knee replacement is planned&#xD;
&#xD;
          -  General health status acceptable for total knee replacement surgery in the opinion of&#xD;
             the investigator&#xD;
&#xD;
          -  Stable medications within 3 months prior to enrollment (such as appropriate pain&#xD;
             medication, antibiotics prophylaxis) and standard of care&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Presence of inflammatory arthropathy (including but not limited to rheumatoid&#xD;
             arthritis, psoriatic arthritis, ankylosing spondylitis, gout), active acute or chronic&#xD;
             infection, or systemic cartilage disorder&#xD;
&#xD;
          -  Prior cartilage repair surgery, e.g. microfracture, autologous cartilage implantation&#xD;
             (ACI) or else, at the same knee&#xD;
&#xD;
          -  Any surgical therapy or local treatment i.a. into the knee (viscosupplementation) to&#xD;
             the knee within 2 months prior to enrollment&#xD;
&#xD;
          -  BMI &gt; 40; presence of uncontrolled diabetes or hyperthyroidism&#xD;
&#xD;
          -  Large effusion in the knee to be replaced, more than (&gt;)1 cm fluid in the&#xD;
             suprapatellar space at the midline&#xD;
&#xD;
          -  Corticosteroid use by any route except topical and nasal in the 3 months prior to&#xD;
             enrollment&#xD;
&#xD;
          -  History of malignancy of any organ system (other than localized basal cell carcinoma&#xD;
             of the skin or in-situ cervical cancer), treated or untreated, within the past 5&#xD;
             years, regardless of whether there is evidence of local recurrence or metastases&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women&#xD;
&#xD;
          -  Women of child-bearing potential, defined as all women physiologically capable of&#xD;
             becoming pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=454</url>
    <description>A Plain Language Trial Summary is available on novartisclinicatrials.com</description>
  </link>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17358</url>
    <description>Results for CLNA043X2101 can be found on the Novartis Clinical Trial Results Website</description>
  </link>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>June 23, 2015</study_first_submitted>
  <study_first_submitted_qc>July 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2015</study_first_posted>
  <last_update_submitted>December 9, 2020</last_update_submitted>
  <last_update_submitted_qc>December 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary Osteoarthritis, Total Knee Replacement, cartilage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

